Medtronic, Inc.  

(Public, NYSE:MDT)   Watch this stock  
Find more results for mdt
63.85
+0.73 (1.16%)
Aug 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 63.06 - 63.86
52 week 51.53 - 65.50
Open 63.42
Vol / Avg. 4.72M/7.13M
Mkt cap 63.61B
P/E 21.12
Div/yield 0.31/1.91
EPS 3.02
Shares 996.19M
Beta 1.11
Inst. own 91%
Nov 17, 2014
Q2 2015 Medtronic Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 8, 2014
Medtronic Inc at Morgan Stanley Healthcare Conference - 3:25PM EDT - Add to calendar
Aug 21, 2014
Medtronic Inc Annual Shareholders Meeting - Webcast
Aug 19, 2014
Q1 2015 Medtronic Inc. Earnings Release
Aug 19, 2014
Q1 2015 Medtronic Inc Earnings Call - Webcast
Aug 6, 2014
Medtronic Inc at Piper Jaffray Heartland Summit(CEO's Perspective, Part 4)
Aug 6, 2014
Medtronic Inc at Piper Jaffray Heartland Summit(CEO's Perspective, Part 1)
Aug 6, 2014
Medtronic Inc at CFA Society of Minnesota's InvestMNt Conference
Jun 17, 2014
Medtronic Inc at Wells Fargo Healthcare Conference - Webcast
Jun 16, 2014
Medtronic to Acquire Covidien Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '14) 2014
Net profit margin 9.81% 18.02%
Operating margin 10.76% 22.42%
EBITD margin - 33.33%
Return on average assets 4.78% 8.42%
Return on average equity 9.26% 16.08%
Employees 49,000 -
CDP Score - 61 D

Address

710 MEDTRONIC PKWY
MINNEAPOLIS, MN 55432
United States - Map
+1-763-5144000 (Phone)
+1-763-5144879 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medtronic, Inc. (Medtronic) is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. Effective August 27, 2014, the Company acquired the remaining 70% interest in NGC Medical SpA, Novedrate-based manufacturer and wholesaler of medical devices.

Officers and directors

Omar Ishrak Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Gary L. Ellis Chief Financial Officer, Senior Vice President
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Carol A. Surface Chief Human Resource Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Michael J. Coyle Executive Vice President, Group President - Cardiac and Vascular Group
Age: 51
Bio & Compensation  - Reuters
Hooman C. Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
Age: 44
Bio & Compensation  - Reuters
Robert ten Hoedt Executive Vice President and President, EMEAC
Age: 53
Bio & Compensation  - Reuters
Christopher J. O'Connell Executive Vice President and Group President - Restorative Therapies Group
Age: 47
Bio & Compensation  - Reuters
Richard E. Kuntz M.D. Senior Vice President, Chief Scientific, Clinical and Regulatory Officer
Age: 57
Bio & Compensation  - Reuters
Bradley E. Lerman Senior Vice President, General Counsel, Corporate secretary
Age: 57
Bio & Compensation  - Reuters
Geoffrey S. Martha Senior Vice President - Strategy and Business Development
Age: 44
Bio & Compensation  - Reuters